Tradestie Institutional Equity Comparison Engine
CRMD vs PVLA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CRMD Overall Edge
CRMD Captures Institutional Edge (2โ2 Pillars ยท 6โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to CorMedix Inc. (CRMD) driven by superior Valuation, Growth & Margin while PVLA counters with relative strength in Momentum & Technical, Options & Structure. Fundamentally, CRMD trades at 49.0x Forward P/E with 41.0% operating margin (-47.7% YoY revenue) versus PVLA at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, CRMD sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro) against PVLA sits in CONSOLIDATION (2nd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
CRMD
CRMD 49.0x vs PVLA N/M Fwd P/E
Growth & Margin Winner
CRMD
Op Margin 41.0% vs 0.0% ยท YoY -47.7% vs +0.0%
Momentum & Technical Winner
PVLA
1Y -56.2% vs +80.2% ยท 52W Pos 3% vs 68%
Options & Structure Winner
PVLA
BREAKDOWN (25th %ile IV) vs CONSOLIDATION (2nd %ile IV)
CRMD
NASDAQ
CorMedix Inc.
Pharmaceutical Preparations
$4.92
+5.47% 1D
Market Cap
$384.7M
1M Return
-32.3%
1Y Return
-56.16%
Forward P/E
49.0x
Unified AI Score
53.2 / 100
HOLD
Tech 60.0
Fund 60.0
Flow 69.0
Mom 55.0
PVLA
NASDAQ
Palvella Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$145.03
-4.89% 1D
Market Cap
$2.2B
1M Return
+20.56%
1Y Return
+80.16%
Forward P/E
N/M
Unified AI Score
48.2 / 100
HOLD
Tech 35.0
Fund 53.0
Flow 67.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CRMD -56.16%
PVLA +80.16%
Spread: +136.32 pp (PVLA Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | CRMD Revenue | PVLA Revenue | CRMD Op. Margin | PVLA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $0M | $30M | -6250.4% | -113.1% | PVLA |
| FY2019 | $0M | $40M | -7416.3% | -62.2% | PVLA |
| FY2020 | $0M | $30M | -11378.4% | -115.7% | PVLA |
| FY2021 | $0M | $30M | -15417.5% | -165.0% | PVLA |
| FY2022 | $0M | $30M | -46819.9% | -167.8% | PVLA |
| FY2023 | N/A | $40M | N/A | -27.7% | PVLA |
| FY2024 | $40M | N/A | -51.4% | N/A | CRMD |
| FY2025 | $310M | N/A | 48.2% | N/A | CRMD |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CRMD | PVLA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $384.7M | $2.2B | Larger Scale | PVLA |
| Trailing P/E Ratio Valuation | 2.4x | N/M | Lower Multiple | CRMD |
| Forward P/E Ratio Valuation | 49.0x | N/M | Lower Multiple | CRMD |
| Revenue Growth (YoY) Growth | -47.7% | +0.0% | Higher Growth | PVLA |
| Operating Margin (TTM) Profitability | 41.0% | 0.0% | Higher Margin | CRMD |
| Net Profit Margin Profitability | 15.5% | 0.0% | Higher Margin | CRMD |
| Return on Equity (ROE) Capital Efficiency | 15.3% | -63.4% | Higher ROE | CRMD |
| 52-Week Range Position Momentum | 3% ($5โ$13) | 68% ($72โ$180) | Stronger Trend | PVLA |
| Beta / 30D Volatility Risk Regime | 1.20ฮฒ ยท 107% Vol | 1.66ฮฒ ยท 75% Vol | Lower Realized Risk | PVLA |
| Unified Institutional Score Composite Signal | 53.2 / 100 (HOLD) | 48.2 / 100 (HOLD) | Higher Composite | CRMD |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CRMD vs PVLA Buy Guide
CRMD
BREAKDOWN
109d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
25th %ile
IV Regime
Compressed (<25th %ile)
PVLA
CONSOLIDATION
70d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
2nd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CRMD nor PVLA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.